English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Book Chapter

Erytropoietin treatment for human stroke is safe and beneficial

MPS-Authors
/persons/resource/persons182138

Ehrenreich,  Hannelore
Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182182

Hasselblatt,  Martin
Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182252

Knerlich,  Friederike
Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182411

Sirén,  Anna-Leena
Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Ehrenreich, H., Hasselblatt, M., Cepek, L., Jacob, S., Knerlich, F., & Sirén, A.-L. (2002). Erytropoietin treatment for human stroke is safe and beneficial. In J. Krieglstein, & S. Klumpp (Eds.), Pharmacology of cerebral ischemia (pp. 515-519). Stuttgart: medpharm Scientific Publ.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0029-0BA3-8
Abstract
There is no abstract available